Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children

Lancet Infectious Diseases

Volumn 4, Issue 8, 2004, Pages 510-518

  Obaro, S K ^a,b,c   Pugatch, D ^a   Luzuriaga, K ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; MUMPS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; TETANUS TOXOID; TOXOID; VARICELLA ZOSTER VACCINE; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; B LYMPHOCYTE ACTIVATION; CELL DIVISION; CELL PROLIFERATION; CHICKENPOX; DIPHTHERIA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HEPATITIS B; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFLUENZA; MEASLES; MEMORY CELL; MUMPS; PERTUSSIS; POLIOMYELITIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RUBELLA; SEROLOGY; SIDE EFFECT; SUPERINFECTION; T LYMPHOCYTE ACTIVATION; TETANUS; VERTICAL TRANSMISSION; VIRUS INFECTION; VIRUS REPLICATION; YELLOW FEVER;

BACTERIAL VACCINES; CHILD, PRESCHOOL; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; INFANT; VACCINATION; VACCINES, ATTENUATED; VACCINES, SUBUNIT; VIRAL VACCINES; VIRUS REPLICATION;

EID: 4043130376     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(04)01106-5     Document Type: Review

References (97)

1. Luzuriaga K, Sullivan J. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev. 4:2002;22-27
2. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 1993; 42: 1-18.
3. Newell ML. Mortality among infected and uninfected infants born to HIV-infected women in Africa: infants, HIV, and mortality in Africa study. 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; 2004. Abstract # 155/Session 29.
4. Zwi KJ, Pettifor JM, Soderlund N. Paediatric hospital admissions at a South African urban regional hospital: the impact of HIV, 1992-1997. Ann Trop Paediatr. 19:1999;135-142
5. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 336:1997;1343-1349
6. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical HIV-1 Infection: Control of viral replication and absence of persistent HIV-1 specific immune responses. J Virol. 74:2000;6984-6991
7. WHO. Global programme for vaccines and immunization, expanded programme on immunization. WHO/EPI/GEN/95.03. 1996;World Health Organization, Geneva
8. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ. 81:2003;61-70
9. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 86:1995;1082-1089
10. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 334:1996;1222-1230
11. Ramilo O, Hicks PJ, Borvak J, et al. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J. 15:1996;197-203
12. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 3:1997;533-540
13. Fogelman I, Davey V, Ochs HD, et al. Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis. 182:2000;435-441
14. Sprent J, Tough DF, Sun S. Factors controlling the turnover of T memory cells. Immunol Rev. 156:1997;79-85
15. Black FL, Rosen L. Patterns of measles antibodies in residents of Tahiti and their stability in the absence of re-exposure. J Immunol. 88:1962;725-731
16. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol. 11:1999;172-179
17. Seddon B, Tomlinson P, Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol. 4:2003;680-686
18. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science. 288:2000;675-678
19. MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine. 17:1999;3086-3093
20. Rubinstein A, Mizrachi Y, Bernstein L, et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients. AIDS. 14:2000;F55-62
21. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 171:2003;4969-4973
22. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine. 21:(suppl 2):2003;S35-37
23. Sun Y, Iglesias E, Samri A, et al. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods. 272:2003;23-34
24. Appay V, Rowland-Jones SL. The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods. 268:2002;9-19
25. De Rosa SC, Brenchley JM, Roederer M. Beyond six colors: a new era in flow cytometry. Nat Med. 9:2003;112-117
26. Borkowsky W, Steele CJ, Grubman S, Moore T, La Russa P, Krasinski K. Antibody responses to bacterial toxoids in children infected with human immunodeficiency virus. J Pediatr. 110:1987;563-566
27. Borkowsky W, Rigaud M, Krasinski K, Moore T, Lawrence R, Pollack H. Cell-mediated and humoral immune responses in children infected with human immunodeficiency virus during the first four years of life. J Pediatr. 120:1992;371-375
28. Krasinski K, Borkowsky W, Bonk S, Lawrence R, Chandwani S. Bacterial infections in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 7:1988;323-328
29. de Martino M, Podda A, Galli L, et al. Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. Vaccine. 15:1997;1235-1238
30. Palme IB, Gudetta B, Bruchfeld J, Muhe L, Giesecke J. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr Infect Dis J. 21:2002;1053-1061
31. Fine PE. BCG: the challenge continues. Scand J Infect Dis. 33:2001;243-245
32. Casanova JL, Jouanguy E, Lamhamedi S, Blanche S, Fischer A. Immunological conditions of children with BCG disseminated infection. Lancet. 346:1995;581
33. Besnard M, Sauvion S, Offredo C, et al. Bacillus Calmette-Guerin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J. 12:1993;993-997
34. Hesseling AC, Schaaf HS, Hanekom WA, et al. Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis. 37:2003;1226-1233
35. BCG vaccination and pediatric HIV infection - Rwanda, 1988-1990. MMWR Morb Mortal Wkly Rep 1991; 40: 833-836.
36. Ota MO, O'Donovan D, Marchant A, et al. HIV-negative infants born to HIV-1 but not HIV-2-positive mothers fail to develop a Bacillus Calmette-Guerin scar. AIDS. 13:1999;996-998
37. Jason J, Archibald LK, Nwanyanwu OC, et al. Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring. Infect Immun. 70:2002;6188-6195
38. Archibald LK, Kazembe PN, Nwanyanwu O, Mwansambo C, Reller LB, Jarvis WR. Epidemiology of bloodstream infections in a bacille Calmette-Guerin-vaccinated pediatric population in Malawi. J Infect Dis. 188:2003;202-208
39. Garly ML, Martins CL, Bale C, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine. 21:2003;2782-2790
40. Cooper WO, Boyce TG, Wright PF, Griffin MR. Do childhood vaccines have non-specific effects on mortality? Bull World Health Organ. 81:2003;821-826
41. Ion-Nedelcu N, Dobrescu A, Strebel PM, Sutter RW. Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet. 343:1994;51-52
42. Chitsike I, van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report. BMJ. 318:1999;841-843
43. Ryder RW, Oxtoby MJ, Mvula M, et al. Safety and immunogenicity of bacille Calmette-Guerin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr. 122:1993;697-702
44. Jura E, Chadwick EG, Josephs SH, et al. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 8:1989;586-590
45. Silliman CC, Tedder D, Ogle JW, et al. Unsuspected varicella-zoster virus encephalitis in a child with acquired immunodeficiency syndrome. J Pediatr. 123:1993;418-422
46. Aldeen T, Hay P, Davidson F, Lau R. Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy. AIDS. 12:1998;1719-1720
47. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 139:2001;305-310
48. Anon. Prevention of varicella. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48 (RR06): 1-5.
49. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 358:2001;121-122
50. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 358:2001;98-104
51. Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 358:2001;91-97
52. Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 16:1997;1177-1179
53. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 267:1992;1237-1241
54. Anon. Measles in HIV-infected children, United States. MMWR Morb Mortal Wkly Rep 1988; 37: 183-186.
55. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 11:1992;1008-1014
56. de Moraes-Pinto MI, Farhat CK, Carbonare SB, et al. Maternally acquired immunity in newborns from women infected by the human immunodeficiency virus. Acta Paediatr. 82:1993;1034-1038
57. Anon. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 1996; 45: 603-06.
58. Goon P, Cohen B, Jin L, Watkins R, Tudor-Williams G. MMR vaccine in HIV-infected children - potential hazards? Vaccine. 19:2001;3816-3819
59. Permar SR, Moss WJ, Ryon JJ, et al. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J Infect Dis. 183:2001;532-538
60. Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA. 261:1989;2512-2516
61. Krugman S. Present status of measles and rubella immunization in the United States: a medical progress report. J Pediatr. 90:1977;1-12
62. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis. 32:2001;1090-1094
63. Embree JE, Datta P, Stackiw W, et al. Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis. 165:1992;262-267
64. Global Programme on AIDS and Expanded Programme on Immunization. Joint WHO/UNICEF statement on early immunization for HIV-infected children. Wkly Epidem Rec 1989; 64: 48-49.
65. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 315:1997;1060-1064
66. Cox NJ, Subbarao K. Influenza. Lancet. 354:1999;1277-1282
67. CDC. HIV/AIDS surveillance report. Atlanta, GA: Centers for Disease Control and Prevention, 1997; 9: 1-43.
68. Tasker SA, O'Brien WA, Treanor JJ, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine. 16:1998;1039-1042
69. Vigano A, Bricalli D, Trabattoni D, et al. Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha. AIDS Res Hum Retroviruses. 14:1998;727-734
70. Zuccotti GV, Cucchi C, Sala D, Giovannini M. Immunogenicity and safety of a virosomal influenza vaccine in HIV-infected children. Acta Paediatr. 91:2002;486
71. Jackson CR, Vavro CL, Valentine ME, et al. Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr Infect Dis J. 16:1997;200-204
72. Keller M, Deveikis A, Cutillar-Garcia M, et al. Pneumococcal and influenza immunization and human immunodeficiency virus load in children. Pediatr Infect Dis J. 19:2000;613-618
73. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 20:(suppl 5):2002;B29-32
74. Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis. 174:(suppl 1):1996;S5-11
75. Hoshino Y, Kapikian AZ. Rotavirus vaccine development for the prevention of severe diarrhoea in infants and young children. Trends Microbiol. 2:1994;242-249
76. de Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull World Health Organ. 63:1985;569-583
77. Saulsbury FT, Winkelstein JA, Yolken RH. Chronic rotavirus infection in immunodeficiency. J Pediatr. 97:1980;61-65
78. Gilger MA, Matson DO, Conner ME, Rosenblatt HM, Finegold MJ, Estes MK. Extraintestinal rotavirus infections in children with immunodeficiency. J Pediatr. 120:1992;912-917
79. Oshitani H, Kasolo FC, Mpabalwani M, et al. Association of rotavirus and human immunodeficiency virus infection in children hospitalized with acute diarrhea, Lusaka, Zambia. J Infect Dis. 169:1994;897-900
80. Cunliffe NA, Gondwe JS, Kirkwood CD, et al. Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian children. Lancet. 358:2001;550-555
81. Anon. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48(RR-2): 1-20.
82. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis. 163:1991;454-459
83. Vazquez-Vizoso F, Eiroa P, Ledo L, Anibarro L, Hernandez M, Ojea R. HIV infection and isolated detection of anti-HBc. Gastroenterology. 106:1994;823-824
84. Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis. 18:1994;339-347
85. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 11:1997;597-606
86. Scolfaro C, Fiammengo P, Balbo L, Madon E, Tovo PA. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS. 10:1996;1169-1170
87. Zuin G, Principi N, Tornaghi R, et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine. 10:1992;857-860
88. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 19:2000;877-885
89. Black SB, Shinefield HR, Fireman B, Hiatt R. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. J Infect Dis. 165:(suppl 1):1992;S139-S143
90. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet. 349:1997;1191-1197
91. Gibb D, Giacomelli A, Masters J, et al. Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection. Pediatr Infect Dis J. 15:1996;1097-1101
92. Read JS, Frasch CE, Rich K, et al. The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women: Women and Infants Transmission Study Group. Pediatr Infect Dis J. 17:1998;391-397
93. Madhi SA, Petersen K, Khoosal M, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J. 21:2002;315-321
94. Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics. 112:2003;66-73
95. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 349:2003;1341-1348
96. Schutze GE, Tucker NC, Mason EO Jr. Failure of the conjugate pneumococcal vaccine to prevent recurrent bacteremia in a child with human immunodeficiency virus disease. Pediatr Infect Dis J. 20:2001;1009-1010
97. Paul Y. Herd immunity and herd protection. Vaccine. 22:2004;301-302